

## SEQUENCE LISTING

<110> Children's Medical Center Corporation  
Ashkar, Samy

<120> Osteopontin-Coated Surfaces and Methods of Use

<130> CMCC 779

<150> US 60/241,248

<151> 2000-10-18

<150> US 60/327,273

<151> 2001-10-05

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 314

<212> PRT

<213> Homo sapiens

<400> 1

Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala  
1 5 10 15

Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu  
20 25 30

Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro  
35 40 45

Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ala Val Ser Ser Glu  
50 55 60

Glu Thr Asn Asp Phe Lys Gln Glu Thr Leu Pro Ser Lys Ser Asn Glu  
65 70 75 80

Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp Asp His  
85 90 95

09981845-101801

09081845.10.1801

Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp  
100 105 110

Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu  
115 120 125

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu  
130 135 140

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly  
145 150 155 160

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg  
165 170 175

Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His  
180 185 190

Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala  
195 200 205

Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser  
210 215 220

Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His  
225 230 235 240

Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu  
245 250 255

His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu  
260 265 270

Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp  
275 280 285



Arg Gly Arg Asp Ser  
1 5

<210> 5  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificial peptide sequence

<400> 5

Gly Arg Gly Asp Ser  
1 5

<210> 6  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificial peptide sequence

<400> 6

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly  
1 5 10 15

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg  
20 25 30

<210> 7  
<211> 33  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Artificial peptide sequence

<400> 7

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly  
1 5 10 15

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg  
 20 25 30

Pro

<210> 8  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 8

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val  
 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser  
 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro  
 35 40

<210> 9  
 <211> 49  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 9

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu  
 1 5 10 15

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly  
 20 25 30

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg  
 35 40 45

Pro

<210> 10  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 10

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val  
 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser  
 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro  
 35 40

<210> 11  
 <211> 63  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 11

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val  
 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser  
 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro Ala Gly Ala Ala Gly Gly Pro Ala  
 35 40 45

Gly Pro Ala Gly Pro Ala Gly Pro Ala Gly Pro Ala Gly Pro Ala  
 50 55 60

<210> 12  
 <211> 36  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 12

Arg Ser Arg Arg Val Phe Thr Pro Phe Ile Pro Thr Glu Ser Ala Asn  
 1 5 10 15

Asp Gly Arg Gly Asp Ser Val Ala Tyr Gly Leu Lys Ser Lys Ser Lys  
 20 25 30

Lys Phe Arg Arg  
 35

<210> 13  
 <211> 32  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 13

Asp Thr Phe Thr Pro Ile Val Pro Thr Val Asp Val Pro Asn Gly Arg  
 1 5 10 15

Phe Asp Ser Leu Ala Tyr Gly Leu Lys Ser Lys Ser Lys Lys Phe Gln  
 20 25 30

<210> 14  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<400> 14

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val  
 1 5 10 15

Asp Thr Tyr Asp Gly Arg Ala Asp Ser Val Val Tyr Gly Arg Arg Ser  
 20 25 30

Lys Ser Lys Lys Phe Arg Arg Pro  
 35 40

<210> 15  
 <211> 40  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Artificial peptide sequence

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Acetyl-modified N-terminus

<400> 15

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val  
 1 5 10 15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser  
 20 25 30

Glu His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg  
1 5 10 15  
Glu Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val  
20 25 30  
Asp Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser  
35 40 45  
His Glu Leu Asp Ser Ala Ser Ser Glu Val Asn  
50 55